- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Glass in Vials Leads to Recall of Several Hospira Products
The presence of glass can lead to serious adverse events, including inflammation of a vein and blockage of blood vessels or life-threatening blood clots.
Hospira is recalling several products because glass particulates were found during product inspection. The presence of glass can lead to serious adverse events, including inflammation of a vein, granuloma, and blockage of blood vessels or life-threatening blood clots.
This recall impacts:
- Bleomycin for Injection, single dose with ONCO-TAIN glass fliptop vial, lot number BL12206A and NDC 61703-332-18. It has an expiration date of June 30, 2024. Bleomycin is used to treat several types of cancer, including head and neck, uterine, cervical, testicular, and lymphoma.
- 4.2% Sodium Biocarbonate Injection, with ABBOJECT glass syringe, lot number GX1542, with NDC for the carton 0409-5534-24 and NDC for the case 0409-5534-14. It has an expiration date of Jan. 1, 2025. It is indicated to treat patients with metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, severe dehydration, , cardiac arrest and severe primary lactic acidosis.
- 8.4% Sodium Biocarbonate Injection, with Lifeshield ABBOJECT glass syringe, lot number HA7295 with NDC for the carton 0409-6637-24 and NDC for the case 0409-6637-14. It has an expiration of March 1, 2025.
- Atropine Sulfate Injection, with Lifeshield ABBOJECT glass syringe, lot number of GY2496 with NDC for the carton 0409-4911-11 and NDC for the case 0409-4911-34. It has an expiration of Feb. 1, 2025. It blocks severe or life-threatening muscarinic effects.
To date, Hospira has not received reports of any adverse events associated with these products.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
